Clinical Trials Browser

NCT07463807 2026-03-19

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

162 enrolled

Plasma cell

Multiple Myeloma

NCT04847453 2026-03-18

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

Phase 1 Recruiting

24 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05272826 2026-03-18

BOREALIS

Phase 2 Recruiting

75 enrolled

Plasma cell

Multiple Myeloma

NCT06169215 2026-03-18

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

70 enrolled

Plasma cell

Multiple Myeloma

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

80 enrolled

Plasma cell

Multiple Myeloma

NCT03798678 2026-03-17

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Phase 1 Active not recruiting

36 enrolled

Plasma cell

Multiple Myeloma

NCT05552976 2026-03-17

SUCCESSOR-2

Phase 3 Active not recruiting

525 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05690984 2026-03-16

EMAT

Phase 2 Active not recruiting

30 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 2 Active not recruiting

30 enrolled

Plasma cell

Multiple Myeloma

NCT06348108 2026-03-13

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

32 enrolled

Plasma cell

Multiple Myeloma

NCT04151667 2026-03-11

Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

33 enrolled 11 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

810 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT04094961 2026-03-05

Ixazomib + Pomalidomide + Dexamethasone In MM

Phase 1/2 Active not recruiting

52 enrolled

Plasma cell

Multiple Myeloma

NCT06203912 2026-03-05

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 1 Active not recruiting

3 enrolled

Plasma cell

Multiple Myeloma

NCT03937635 2026-03-02

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Phase 3 Recruiting

288 enrolled

Plasma cell

Smoldering Multiple Myeloma

NCT04566328 2026-03-02

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3 Recruiting

1,450 enrolled

Plasma cell

Multiple Myeloma

NCT04764942 2026-02-25

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial

Phase 1/2 Active not recruiting

39 enrolled

Plasma cell

Multiple Myeloma

NCT05530421 2026-02-23

SELVEDge

Phase 2 Recruiting

33 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Phase 2 Recruiting

100 enrolled

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT07428369 2026-02-23

LINKER-MM8

Phase 2/3 Not yet recruiting

1,570 enrolled

Plasma cell

Multiple Myeloma

NCT01297764 2026-02-19

QUAD

Phase 1/2 Active not recruiting

17 enrolled

Plasma cell

Multiple Myeloma

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Not yet recruiting

21 enrolled

Plasma cell

Multiple Myeloma